PAR Pharmaceutical  
ProfilePrioritiesParFactsGenericsAlliancesAwardsHistory

About ParProductsInvestorsMediaCustomersCareers
Home / About Par / History

Introduction
2006
  • Par announces 2005 revenue of $433.2 million
  • Par begins shipment of generic Flonase® (fluticasone) Nasal Spray
  • Par announces product collaboration with Spectrum Pharmaceuticals

2005

  • Par launches first specialty brand — Megace® ES (megestrol acetate)
  • Par forms alliance with Optimer Pharmaceuticals to develop and market PAR-101, a novel antibiotic
  • Par introduces 15 new generic products and, with its partner companies, files 22 new ANDAs
  • Par announces record revenues of $690.0 million for 2004

2004

  • Par ranked fourth for revenue growth, 10th for earnings per share growth, and 20th overall in the Fortune list of America's 100 Fastest Growing Companies
  • Par wins Healthcare Distribution Management Association's DIANA award for "Best Overall Pharmaceutical Products Manufacturer"
  • Par introduces 17 new generic products and, with its partner companies, files 34 new ANDAs and two NDAs

2003

  • PRX achieves market cap of $2.2 billion

2002

  • PRX ranked as top-performing stock on NYSE for 2001 by Associated Press
  • Par wins prestigious DIANA Award from Healthcare Distribution Management Association

1987

  • PRX listed on New York Stock Exchange

1978

  • Par Pharmaceutical founded